| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.5306/WJCO.V5.I5.1002 |
| P8608 | Fatcat ID | release_rieu55qlovhkngz445tl4hc7ua |
| P932 | PMC publication ID | 4259927 |
| P698 | PubMed publication ID | 25493236 |
| P5875 | ResearchGate publication ID | 269416345 |
| P2093 | author name string | Carlos Rosales | |
| Ricardo Rosales | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Surgery for cervical intraepithelial neoplasia | Q24234819 | ||
| Therapy of human papillomavirus-related disease | Q27007473 | ||
| Screening for cervical cancer | Q74566735 | ||
| Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum | Q82938166 | ||
| Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells | Q84749415 | ||
| Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? | Q27692056 | ||
| Imiquimod applied topically: a novel immune response modifier and new class of drug | Q28140002 | ||
| Imiquimod: modes of action | Q28184438 | ||
| Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway | Q28216760 | ||
| Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 | ||
| Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus | Q28261838 | ||
| Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream | Q28269272 | ||
| A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007 | Q28306947 | ||
| Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial | Q28750269 | ||
| Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug | Q29396548 | ||
| Toll-like receptors and their crosstalk with other innate receptors in infection and immunity | Q29547722 | ||
| HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial | Q30538743 | ||
| Surgery for cervical intraepithelial neoplasia. | Q30868271 | ||
| Critical appraisal of commonly used treatment for genital warts | Q31075776 | ||
| Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype | Q33218333 | ||
| The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha | Q33292312 | ||
| Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. | Q33292449 | ||
| A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod | Q33668568 | ||
| Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. | Q33692334 | ||
| Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia | Q33783092 | ||
| A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. | Q33834057 | ||
| Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes | Q33839638 | ||
| Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes | Q33851664 | ||
| Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art | Q33907628 | ||
| Th1 cytokine patterns in cervical human papillomavirus infection. | Q33997914 | ||
| Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? | Q34029941 | ||
| Immunotherapy for cervical cancer: Research status and clinical potential | Q34033763 | ||
| The 2001 Bethesda System: terminology for reporting results of cervical cytology | Q34124761 | ||
| Worldwide burden of cervical cancer in 2008. | Q34176394 | ||
| 2012 European guideline for the management of anogenital warts | Q34260588 | ||
| Immunity to oncogenic human papillomaviruses | Q34305225 | ||
| High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
| The natural history of cervical HPV infection: unresolved issues | Q36691070 | ||
| Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects | Q36949240 | ||
| 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests | Q36955449 | ||
| Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines | Q37140636 | ||
| Tumor-specific regulatory T cells in cancer patients | Q37166643 | ||
| The papillomavirus E2 proteins | Q37198619 | ||
| Host immune responses to cervical cancer | Q37362937 | ||
| Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions | Q37492600 | ||
| Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma | Q37542216 | ||
| Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein | Q37545001 | ||
| Immune responses to human papilloma viruses. | Q37630155 | ||
| Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options | Q37771396 | ||
| Monitoring of human papillomavirus vaccination. | Q37808256 | ||
| Molecular pathogenesis of cervical cancer | Q37829262 | ||
| CD8(+) T cells: foot soldiers of the immune system | Q37922333 | ||
| Nucleic acid tests for the detection of alpha human papillomaviruses | Q38064057 | ||
| New technologies and procedures for cervical cancer screening | Q38064058 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| The biology and life-cycle of human papillomaviruses. | Q38064068 | ||
| Recombinant MVA vaccines: dispelling the myths | Q38092468 | ||
| Clinical development of Modified Vaccinia virus Ankara vaccines | Q38092470 | ||
| Taxonomy and phylogeny of papillomaviruses: an overview and recent developments | Q38092518 | ||
| Latent papillomavirus infections and their regulation | Q38118449 | ||
| Clinical applications of attenuated MVA poxvirus strain. | Q38156198 | ||
| Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia | Q39296306 | ||
| Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer | Q39327918 | ||
| Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins | Q39389688 | ||
| Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. | Q39982103 | ||
| Papillomavirus infections and human genital cancer | Q40127109 | ||
| Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 | ||
| Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial | Q40312191 | ||
| Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients | Q40570530 | ||
| Therapeutic immunisation with COPV early genes by epithelial DNA delivery | Q40626996 | ||
| Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells | Q40797208 | ||
| The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha | Q40842174 | ||
| Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 | ||
| The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. | Q41354966 | ||
| Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream | Q41703681 | ||
| Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression. | Q42030463 | ||
| Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles | Q42691805 | ||
| Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease | Q43240928 | ||
| Polyphenon E: a new treatment for external anogenital warts | Q43285635 | ||
| Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. | Q43300658 | ||
| HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. | Q43438121 | ||
| Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women | Q43655015 | ||
| Six-month natural history of oral versus cervical human papillomavirus infection | Q43781183 | ||
| A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity | Q44005009 | ||
| Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection | Q44238190 | ||
| CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia | Q44310727 | ||
| Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | Q44653310 | ||
| Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia | Q45142471 | ||
| Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients | Q45392367 | ||
| Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). | Q45400945 | ||
| Treatment of genital warts with an immune-response modifier (imiquimod). | Q46023904 | ||
| Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. | Q46024950 | ||
| Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy | Q46240097 | ||
| A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. | Q46564278 | ||
| A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals | Q46732942 | ||
| Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination | Q47637442 | ||
| Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial | Q48708921 | ||
| Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. | Q50850972 | ||
| Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. | Q51820508 | ||
| TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. | Q53336537 | ||
| Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. | Q53342013 | ||
| Human papillomavirus and cervical cancer | Q54023273 | ||
| A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions | Q56770293 | ||
| Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia | Q56901030 | ||
| Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7 | Q58813759 | ||
| Antibodies against Human Papillomavirus Type 16 and 18 E6 and E7 Proteins in Cervicovaginal Washings and Serum of Patients with Cervical Neoplasia | Q58813782 | ||
| Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix | Q59390039 | ||
| Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 | Q60321491 | ||
| Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine | Q61626178 | ||
| Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter | Q61626294 | ||
| Spontaneous Regression of Grade 3 Vulvar Intraepithelial Neoplasia Associated with Human Papillomavirus-16–Specific CD4+and CD8+T-Cell Responses | Q61764195 | ||
| In situ hybridization analysis of human papillomavirus DNA segregation patterns in lesions of the female genital tract | Q68447625 | ||
| Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis | Q70453258 | ||
| Comparison of office loop electrosurgical conization and cold knife conization | Q73110369 | ||
| Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial | Q73112587 | ||
| Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites | Q73698295 | ||
| Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells | Q73699282 | ||
| The treatment of human papillomavirus lesions of the lower genital tract | Q34374068 | ||
| Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. | Q34410767 | ||
| Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer | Q34527281 | ||
| HPV innate immunity | Q34775767 | ||
| Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential | Q35015851 | ||
| Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review | Q35109957 | ||
| Clinical applications of DNA vaccines: current progress | Q35452312 | ||
| European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts | Q35528570 | ||
| A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions | Q35588773 | ||
| ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial | Q35644707 | ||
| The biology of cytomegalovirus drug resistance | Q35684511 | ||
| Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen | Q35771332 | ||
| Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques | Q35771342 | ||
| Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. | Q35901282 | ||
| The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice | Q35913709 | ||
| Close encounters of different kinds: dendritic cells and NK cells take centre stage | Q36028182 | ||
| Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III | Q36052694 | ||
| Therapy for genital human papillomavirus-related disease | Q36064319 | ||
| Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers | Q36099498 | ||
| Electrofulguration for low-grade squamous intraepithelial lesions of the cervix (CIN 1). | Q36116814 | ||
| Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer | Q36128026 | ||
| A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions | Q36189261 | ||
| Immune responses to human papillomavirus | Q36283939 | ||
| Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma | Q36319582 | ||
| The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer | Q36380406 | ||
| Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. | Q36410856 | ||
| Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls | Q36417513 | ||
| T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis. | Q36465254 | ||
| Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. | Q36483341 | ||
| Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach | Q36540533 | ||
| Chapter 2: The burden of HPV-related cancers | Q36584354 | ||
| Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease | Q36584416 | ||
| Mechanisms of cancer prevention by green and black tea polyphenols | Q36611731 | ||
| P433 | issue | 5 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1002-1019 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | World journal of clinical oncology | Q27723540 |
| P1476 | title | Immune therapy for human papillomaviruses-related cancers | |
| P478 | volume | 5 |
| Q38386055 | An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia |
| Q42700753 | Binase treatment increases interferon sensitivity and apoptosis in SiHa cervical carcinoma cells by downregulating E6 and E7 human papilloma virus oncoproteins |
| Q37269385 | Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase. |
| Q38743922 | Current state in the development of candidate therapeutic HPV vaccines |
| Q47576731 | Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. |
| Q33696724 | HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities |
| Q36252874 | HPV prophylactic vaccination in males improves the clearance of semen infection |
| Q36218123 | Human Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia |
| Q36275846 | Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay |
| Q52797663 | Immunotolerant indoleamine-2,3-dioxygenase is increased in condyloma acuminata. |
| Q37406428 | Inhibition of antiviral drug cidofovir on proliferation of human papillomavirus-infected cervical cancer cells |
| Q90863518 | MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis |
| Q47806987 | PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. |
| Q92715593 | Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System |
| Q35928588 | Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines |
| Q90090382 | Prevalence of human papillomavirus infection in oocyte donors and women treated for infertility: An observational laboratory-based study |
| Q39354756 | Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X. |
| Q40517920 | Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine |
| Q61809644 | The molecular biology and HPV drug responsiveness of cynomolgus macaque papillomaviruses support their use in the development of a relevant in vivo model for antiviral drug testing |
| Q39212773 | Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. |
| Q33730462 | hrHPV E5 oncoprotein: immune evasion and related immunotherapies. |
Search more.